We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Proton Craniospinal Irradiation Improves CNS Progression-Free and Overall Survival in Leptomeningeal Metastasis: Randomized Phase 2 Evidence

MedXY Editorial Team•Dec 11, 2025•news
leptomeningeal metastasisRadiotherapy

Highlight

• In a randomized phase 2 trial (NCT04343573), proton craniospinal irradiation (pCSI) prolonged median central nervous system progression‑free survival (CNS‑PFS) to 8.2 months versus 2.3 months with involved‑field photon radiotherapy (IFRT) (P < .001).

• Median overall survival (OS) was significantly longer with pCSI (11.3 months) than IFRT (4.9 months) (P = .04).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

National Health Systems and Their Crucial Role in Reducing Lung Cancer Mortality: Insights from Global DataThis article explores how health system factors like spending, workforce density, and radiotherapy availability influence lung cancer mortality worldwide, highlighting actionable targets for improving outcomes globally.Sep 1, 2026Neoadjuvant Chemotherapy with or without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Impact on OutcomesA propensity-matched study shows adding radiotherapy to neoadjuvant chemotherapy improves pathologic response but does not enhance survival or reduce recurrence in resected pancreatic ductal adenocarcinoma.Aug 31, 2026Lenalidomide and Oral Azacitidine Combined with Radiotherapy in Plasmacytoma: A Pilot Trial and PerspectivesThis review synthesizes evidence on combining lenalidomide and oral azacitidine with radiotherapy for plasmacytoma, highlighting safety, preliminary efficacy, and translational rationale in newly diagnosed and relapsed patients.Aug 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
Aug 10, 2026
Global Consensus 2026: Updated Multidisciplinary Guidance for Primary Localized ChordomaAn accessible, clinician-oriented summary of the 2026 Global Chordoma Consensus—multidisciplinary, anatomy-stratified recommendations on diagnosis, surgery, high‑dose conformal radiotherapy, follow-up, and supportive care for localized chorJul 9, 2026
Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose MetricsEmerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-terJul 2, 2026